CL2021001199A1 - Composiciones filtrables de conjugados anticuerpo-fármaco que contienen duocarmicina y métodos relacionados. - Google Patents

Composiciones filtrables de conjugados anticuerpo-fármaco que contienen duocarmicina y métodos relacionados.

Info

Publication number
CL2021001199A1
CL2021001199A1 CL2021001199A CL2021001199A CL2021001199A1 CL 2021001199 A1 CL2021001199 A1 CL 2021001199A1 CL 2021001199 A CL2021001199 A CL 2021001199A CL 2021001199 A CL2021001199 A CL 2021001199A CL 2021001199 A1 CL2021001199 A1 CL 2021001199A1
Authority
CL
Chile
Prior art keywords
duocarmycin
filterable
compositions
drug conjugates
related methods
Prior art date
Application number
CL2021001199A
Other languages
English (en)
Inventor
Den Hoef Carolus Johannes Edgar Van
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of CL2021001199A1 publication Critical patent/CL2021001199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los conjugados de anticuerpo-fármaco a base de duocarmicina se pueden separar fácilmente de fármaco enlazador de duocarmicina no conjugado en una composición que contenga un sistema de solventes de agua y acetonitrilo y que contenga de 30 % a 60 % de acetonitrilo.
CL2021001199A 2018-11-09 2021-05-06 Composiciones filtrables de conjugados anticuerpo-fármaco que contienen duocarmicina y métodos relacionados. CL2021001199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18205459 2018-11-09

Publications (1)

Publication Number Publication Date
CL2021001199A1 true CL2021001199A1 (es) 2021-12-17

Family

ID=64270729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001199A CL2021001199A1 (es) 2018-11-09 2021-05-06 Composiciones filtrables de conjugados anticuerpo-fármaco que contienen duocarmicina y métodos relacionados.

Country Status (21)

Country Link
US (1) US20210386867A1 (es)
EP (1) EP3876997B1 (es)
JP (1) JP2022506860A (es)
KR (1) KR20210091752A (es)
CN (1) CN112969478B (es)
AU (1) AU2019376457A1 (es)
BR (1) BR112021008293A2 (es)
CA (1) CA3118788A1 (es)
CL (1) CL2021001199A1 (es)
DK (1) DK3876997T3 (es)
ES (1) ES2926980T3 (es)
HR (1) HRP20221197T1 (es)
HU (1) HUE059919T2 (es)
IL (1) IL282913B1 (es)
LT (1) LT3876997T (es)
MX (1) MX2021005484A (es)
PL (1) PL3876997T3 (es)
PT (1) PT3876997T (es)
SG (1) SG11202104413TA (es)
WO (1) WO2020094561A1 (es)
ZA (1) ZA202102798B (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN102317283A (zh) 2008-11-03 2012-01-11 辛塔佳股份有限公司 新型cc-1065类似物及其缀合物
MX336853B (es) 2010-04-21 2016-01-19 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
RU2016117810A (ru) * 2013-10-11 2017-11-17 Асана Биосайенсис, Ллк Конъюгаты белок-полимер-лекарственное средство
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
AU2015205509B2 (en) * 2014-01-10 2019-08-15 Byondis B.V. Duocarmycin ADCs showing improved in vivo antitumor activity
US10407743B2 (en) 2014-05-22 2019-09-10 Synthon Biopharmaceuticals B.V. Site-specific conjugation of linker drugs to antibodies and resulting ADCs
CN106458892B (zh) * 2014-06-05 2019-10-18 斯索恩生物制药有限公司 用于制备倍癌霉素前药的改进方法
AU2016292759B2 (en) * 2015-07-10 2021-05-20 Byondis B.V. Compositions comprising antibody-duocarmycin drug conjugates
ES2854298T3 (es) * 2015-09-22 2021-09-21 Byondis Bv Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1
JP6412906B2 (ja) * 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 化合物、リンカー−薬物およびリガンド−薬物複合体

Also Published As

Publication number Publication date
US20210386867A1 (en) 2021-12-16
JP2022506860A (ja) 2022-01-17
ZA202102798B (en) 2022-08-31
SG11202104413TA (en) 2021-05-28
PL3876997T3 (pl) 2022-12-19
CN112969478A (zh) 2021-06-15
KR20210091752A (ko) 2021-07-22
CA3118788A1 (en) 2020-05-14
AU2019376457A1 (en) 2021-05-27
HUE059919T2 (hu) 2023-01-28
WO2020094561A1 (en) 2020-05-14
BR112021008293A2 (pt) 2021-08-03
MX2021005484A (es) 2021-06-18
EP3876997A1 (en) 2021-09-15
IL282913A (en) 2021-06-30
ES2926980T3 (es) 2022-10-31
LT3876997T (lt) 2022-11-10
HRP20221197T1 (hr) 2022-12-09
DK3876997T3 (da) 2022-09-26
CN112969478B (zh) 2023-10-27
IL282913B1 (en) 2024-03-01
PT3876997T (pt) 2022-11-11
EP3876997B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
EA201791461A1 (ru) Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение
CL2021002378A1 (es) Conjugados de anticuerpo modulador de empalme - fármaco y métodos de uso. (divisional de solicitud 202003117)
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112016002829A2 (pt) Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
PH12016502509A1 (en) Her2 antibody-drug conjugates
AR123672A2 (es) Conjugados de anticuerpo fármaco
CY1124913T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
NZ725131A (en) Tubulysin derivatives
WO2016064749A3 (en) Antibody-drug conjugates and related compounds, compositions, and methods of use
CU20190061A7 (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
ECSP21089206A (es) Conjugados de anticuerpo y fármaco
NZ610239A (en) Cross-linkers and their uses
MX2020004338A (es) Composiciones de peptidos tau fosforilados y sus usos.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CL2021001534A1 (es) Herboxidieno de conjugados de anticuerpo-fármaco y métodos de uso.
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
MX2019006670A (es) Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos.
CO2023006136A2 (es) Conjugados de anticuerpo y fármaco
CL2018003114A1 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
ECSP034838A (es) Inmunoconjugados del anticuerpo cd44 citotoxico